When looking at the launch of Axsome's Auvelity for MDD, it is important to note the week 1 to week 2 change of prescriptions percentage. This could give us a general indication of trajectory of public uptake. From below, and courtesy of research analyst Mizohu, is Auvelity compared to other recent Major Depression drug launches. The table is somewhat hard to read, the week 2 change from week 1 in total prescriptions (TRx's via IQVIA) is 394% w/w change (32 to 158), which is impressive. We will keep tracking Auvelity's launch, but for right now, it's very positive. Again, thanks to Mizuho for the market research. Please click on the table below, for better viewing.
No comments:
Post a Comment